评估局部晚期非小细胞肺癌患者基于个体化疗效反应放疗毒性的2期试验
这项单机构前瞻性2期试验纳入47例IIA至III期不可切除非小细胞肺癌患者,在放化疗期间结合通气-灌注SPECT与FDG-PET进行基于疗效反应的自适应放疗,总剂量至80.4 Gy。主要终点为≥2级肺及食管毒性;1年2级和3级放射性肺炎发生率分别为21.3%和2.1%,2级食管炎为66.0%,无3级食管毒性;1年和2年局部控制率分别为94.5%和87.5%。
要点
- 基于疗效反应的自适应剂量递增放疗联合化放疗,1年2级和3级放射性肺炎发生率分别为21.3%和2.1%。
- 未出现3级食管毒性,但2级食管炎发生率为66.0%。
- 1年和2年局部控制率分别为94.5%(95% CI,87.4%-100%)和87.5%(95% CI,76.7%-100%)。
核心结论
- 基于疗效反应的自适应剂量递增放疗考虑了治疗期间肿瘤变化和正常组织功能,提供了优异的局部控制,毒性可与标准化放疗相当,且联合辅助免疫治疗未增加毒性。
研究设计与样本
- 单机构前瞻性2期试验(NCT02492867)纳入47例IIA至III期不可切除非小细胞肺癌患者。
- 患者接受同步化放疗联合基于个体化疗效反应的自适应放疗,共30次,整合通气-灌注SPECT和FDG-PET。
- 前21次(46.2 Gy,2.2 Gy/次)照射肿瘤并尽量减少SPECT定义的功能肺剂量,随后根据治疗中期FDG-PET肿瘤反应调整计划,最后9次(2.2-3.8 Gy/次)至总剂量80.4 Gy。
- 未进展的患者接受卡铂、紫杉醇或多西他赛?巩固治疗。
主要发现
- 治疗后1年,2级和3级放射性肺炎发生率分别为21.3%和2.1%,接受与未接受辅助度伐利尤单抗患者的肺炎发生率无差异(P = .74)。
- 无3级食管毒性,但66.0%的患者发生2级食管炎。
- 1年和2年局部控制率分别为94.5%(95% CI,87.4%-100%)和87.5%(95% CI,76.7%-100%)。
- 1年和2年总生存率分别为82.8%(95% CI,72.6%-94.4%)和62.3%(95% CI,49.6%-78.3%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Local failure rates after treatment for locally advanced non-small cell lung cancer (NSCLC) remain high. Efforts to improve local control with a uniform dose escalation or dose escalation to midtreatment positron emission tomography (PET)-avid residual disease have been limited by heightened toxicity. This trial aimed to refine response-based adaptive radiation therapy (RT) and minimize toxicity by incorporating fluorodeoxyglucose-PET (FDG-PET) and ventilation-perfusion single-photon emission computed tomography (SPECT) imaging midtreatment. METHODS AND MATERIALS: A total of 47 patients with stage IIA to III unresectable NSCLC were prospectively enrolled in this single-institution trial (NCT02492867). Patients received concurrent chemoradiation therapy with personalized response-based adaptive RT over 30 fractions incorporating ventilation-perfusion single-photon emission computed tomography and FDG-PET. The first 21 fractions (46.2 Gy at 2.2 Gy/fraction) were delivered to the tumor while minimizing the dose to the SPECT-defined functional lung. The plan was then adapted for the final 9 fractions (2.2-3.8 Gy/fraction) up to a total of 80.4 Gy, based on the midtreatment FDG-PET tumor response to escalate the dose to the residual tumor while minimizing the dose to the SPECT-defined functional lung. Nonprogressing patients received consolidative carboplatin, paclitaxel, or durvalumab. The primary endpoint of the study was ≥ grade 2 lung and esophageal toxicities. Secondary endpoints included time to local progression, tumor response, and overall survival. RESULTS: At 1 year posttreatment, the rates of grade 2 and grade 3 pneumonitis were 21.3% and 2.1%, respectively, with no difference in pneumonitis rates among patients who received and did not receive adjuvant durvalumab (P = .74). Although there were no grade 3 esophageal-related toxicities, 66.0% of patients experienced grade 2 esophagitis. The 1- and 2-year local control rates were 94.5% (95% CI, 87.4%-100%) and 87.5% (95% CI, 76.7%-100%), respectively. Overall survival was 82.8% (95% CI, 72.6%-94.4%) at 1 year and 62.3% (95% CI, 49.6%-78.3%) at 2 years. CONCLUSIONS: Response-based adaptive dose-escalation accounting for tumor change and normal tissue function during treatment provided excellent local control, comparable toxicity to standard chemoradiation therapy, and did not increase toxicity with adjuvant immunotherapy.
引用
- Edwards DM, Schonewolf CA, Rice JD, et al. Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38971385. doi:10.1016/j.ijrobp.2024.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。